PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma logoPDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PDLI
  • CUSIP: 69329Y10
  • Web: www.pdl.com
Capitalization:
  • Market Cap: $539.28 million
  • Outstanding Shares: 154,080,000
Average Prices:
  • 50 Day Moving Avg: $3.32
  • 200 Day Moving Avg: $2.63
  • 52 Week Range: $1.93 - $3.77
P/E:
  • Trailing P/E Ratio: 8.02
  • Foreward P/E Ratio: 8.54
  • P/E Growth: 0.40
Sales & Book Value:
  • Annual Revenue: $143.37 million
  • Price / Sales: 3.76
  • Book Value: $5.31 per share
  • Price / Book: 0.66
Profitability:
  • EBITDA: $69.37 million
  • Net Margins: 23.03%
  • Return on Equity: 9.07%
  • Return on Assets: 5.64%
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 1.94%
  • Quick Ratio: 1.90%
Misc:
  • Average Volume: 1.93 million shs.
  • Beta: 0.49
  • Short Ratio: 16.35
 

Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma declared that its Board of Directors has initiated a share buyback plan on Monday, September 25th 2017, which authorizes the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) posted its earnings results on Thursday, August, 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.17. The firm earned $143.80 million during the quarter, compared to the consensus estimate of $56.30 million. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The company's revenue was up 584.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. View PDL BioPharma's Earnings History.

When will PDL BioPharma make its next earnings announcement?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for PDL BioPharma.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

2 analysts have issued 12 month target prices for PDL BioPharma's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate PDL BioPharma's share price to reach $4.00 in the next twelve months. View Analyst Ratings for PDL BioPharma.

What are analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • 1. According to Zacks Investment Research, "PDL BioPharma’s earnings in the second quarter of 2017 surpassed estimates. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, wherein, it is making equity investments in product-focused companies. The company’s royalty agreement with oncology-focused company, ARIAD, is also encouraging. PDL BioPharma’s shares have outperformed the industry in a year. However, the company is heavily dependent on its partners for royalty revenues, which is hardly a risk-free strategy. We are also concerned about PDL BioPharma’s revenue stream in the futureas its growth prospects rely on the timing and ability to acquire new income-generating assets in order to provide recurring revenues." (8/16/2017)
  • 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Are investors shorting PDL BioPharma?

PDL BioPharma saw a increase in short interest in September. As of September 15th, there was short interest totalling 19,901,835 shares, an increase of 9.7% from the August 31st total of 18,146,418 shares. Based on an average daily volume of 2,224,175 shares, the short-interest ratio is currently 8.9 days. Currently, 13.3% of the company's stock are short sold.

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:

  • Dominique Monnet, President
  • John Peter McLaughlin, Chief Executive Officer, Director
  • Peter S. Garcia, Chief Financial Officer, Vice President
  • Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance
  • Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary
  • Danny Hart, Vice President - Business Development
  • Harold E. Selick Ph.D., Lead Independent Director
  • Paul R. Edick, Independent Director
  • David W. Gryska, Independent Director
  • Jody S. Lindell, Independent Director

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Shell Asset Management Co. (0.16%) and Eqis Capital Management Inc. (0.14%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Shell Asset Management Co.. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDL BioPharma stock can currently be purchased for approximately $3.50.


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $4.00 (14.29% upside)
Consensus Price Target History for PDL BioPharma (NASDAQ:PDLI)
Price Target History for PDL BioPharma (NASDAQ:PDLI)
Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00MediumView Rating Details
5/3/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for PDL BioPharma (NASDAQ:PDLI)
Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)
Earnings History by Quarter for PDL BioPharma (NASDAQ PDLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.13N/AView Earnings Details
8/3/2017Q2 2017$0.09$0.26$56.30 million$143.80 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.61 EPS
Next Year EPS Consensus Estimate: $0.41 EPS

Dividends

Dividend History by Quarter for PDL BioPharma (NASDAQ PDLI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 83.34%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PDL BioPharma (NASDAQ:PDLI)
Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
Source:
DateHeadline
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 19 at 1:24 PM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Expected to Announce Earnings of $0.13 Per Share
www.americanbankingnews.com - October 12 at 10:30 PM
nasdaq.com logoAmgen Label Expansion Application for Prolia Accepted by FDA - Nasdaq
www.nasdaq.com - October 11 at 6:30 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 11:49 PM
finance.yahoo.com logoPDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
finance.yahoo.com - October 3 at 10:31 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : September 28, 2017
finance.yahoo.com - October 3 at 10:31 AM
finance.yahoo.com logoSeattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
finance.yahoo.com - October 3 at 10:31 AM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 28 at 3:18 AM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:08 PM
streetinsider.com logoPDL BioPharma (PDLI) Reports $25M Share Buyback Program
www.streetinsider.com - September 25 at 5:01 PM
americanbankingnews.com logoStock Buyback Plan Declared by PDL BioPharma (PDLI) Board of Directors
www.americanbankingnews.com - September 25 at 11:24 AM
finance.yahoo.com logoPDL BioPharma Announces New $25 Million Share Repurchase Program
finance.yahoo.com - September 25 at 10:53 AM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 24 at 1:16 PM
americanbankingnews.com logoHead-To-Head Comparison: PDL BioPharma (PDLI) versus The Competition
www.americanbankingnews.com - September 23 at 10:22 AM
nasdaq.com logoShould Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock? - Nasdaq
www.nasdaq.com - September 22 at 8:40 AM
finance.yahoo.com logoPluristem's Ischemia Candidate Gets Fast Track Designation
finance.yahoo.com - September 20 at 7:34 AM
finance.yahoo.com logoPDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference
finance.yahoo.com - September 20 at 7:34 AM
americanbankingnews.com logoFinancial Contrast: PDL BioPharma (PDLI) vs. Charles River Laboratories International (CRL)
www.americanbankingnews.com - September 19 at 8:52 AM
finance.yahoo.com logo3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
finance.yahoo.com - September 15 at 7:29 AM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Sees Large Increase in Short Interest
www.americanbankingnews.com - September 14 at 1:46 AM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 7:40 AM
finance.yahoo.com logoPDL BioPharma Appoints Dominique Monnet as President
finance.yahoo.com - September 12 at 8:28 AM
seekingalpha.com logoPDL BioPharma: Q2 Update - Seeking Alpha
seekingalpha.com - September 7 at 7:32 AM
americanbankingnews.com logo$0.13 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - September 5 at 12:14 PM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 30 at 1:00 PM
nasdaq.com logoWhy PDL BioPharma (PDLI) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - August 29 at 6:35 AM
finance.yahoo.com logoWhy PDL BioPharma (PDLI) Could Be Positioned for a Surge
finance.yahoo.com - August 29 at 6:35 AM
finance.yahoo.com logo5 Bargain Breakout Stocks Offering Stunning Returns
finance.yahoo.com - August 24 at 10:54 AM
nasdaq.com logo3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq
www.nasdaq.com - August 19 at 6:26 AM
nasdaq.com logo3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock - Nasdaq
www.nasdaq.com - August 19 at 6:26 AM
finance.yahoo.com logo3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
finance.yahoo.com - August 19 at 6:25 AM
finance.yahoo.com logo3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
finance.yahoo.com - August 19 at 6:25 AM
americanbankingnews.com logo$0.08 EPS Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - August 18 at 12:20 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 6:09 AM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Releases Earnings Results, Beats Expectations By $0.17 EPS
www.americanbankingnews.com - August 5 at 6:44 PM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 5 at 1:28 PM
fool.com logoHere's Why PDL BioPharma Inc. Is Soaring Today - Motley Fool
www.fool.com - August 5 at 6:03 AM
finance.yahoo.com logoHere's Why PDL BioPharma Inc. Is Soaring Today
finance.yahoo.com - August 5 at 6:03 AM
fool.com logoHere's Why PDL BioPharma Inc. Is Soaring Today
www.fool.com - August 4 at 2:03 PM
rttnews.com logoEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q2 Earnings Report
www.rttnews.com - August 4 at 6:53 AM
finance.yahoo.com logoPDL BioPharma Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:52 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 6:52 AM
finance.yahoo.com logoEdited Transcript of PDLI earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 6:52 AM
finance.yahoo.com logoPDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : August 4, 2017
finance.yahoo.com - August 4 at 6:52 AM
finance.yahoo.com logoPDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - August 1 at 1:47 AM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 31, 2017
finance.yahoo.com - August 1 at 1:46 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:47 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 21, 2017
finance.yahoo.com - July 22 at 7:29 AM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Short Interest Up 13.0% in June
www.americanbankingnews.com - July 15 at 7:16 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:19 AM

Social

Chart

PDL BioPharma (PDLI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.